HK1085511A1 - Complement inhibitors from ticks - Google Patents

Complement inhibitors from ticks

Info

Publication number
HK1085511A1
HK1085511A1 HK06105580.9A HK06105580A HK1085511A1 HK 1085511 A1 HK1085511 A1 HK 1085511A1 HK 06105580 A HK06105580 A HK 06105580A HK 1085511 A1 HK1085511 A1 HK 1085511A1
Authority
HK
Hong Kong
Prior art keywords
complement inhibitors
ticks
complement
relates
inhibitors
Prior art date
Application number
HK06105580.9A
Other languages
English (en)
Inventor
Miles Andrew Nunn
Original Assignee
Varleigh Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312619A external-priority patent/GB0312619D0/en
Priority claimed from GB0327386A external-priority patent/GB0327386D0/en
Application filed by Varleigh Ltd filed Critical Varleigh Ltd
Publication of HK1085511A1 publication Critical patent/HK1085511A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43552—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
    • G01N2333/43556—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects from ticks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/42—Poisoning, e.g. from bites or stings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
HK06105580.9A 2003-06-02 2006-05-15 Complement inhibitors from ticks HK1085511A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0312619A GB0312619D0 (en) 2003-06-02 2003-06-02 Complement inhibitors
GB0327386A GB0327386D0 (en) 2003-11-25 2003-11-25 Complement inhibitors
PCT/GB2004/002341 WO2004106369A2 (en) 2003-06-02 2004-06-02 Complement inhibitors from ticks

Publications (1)

Publication Number Publication Date
HK1085511A1 true HK1085511A1 (en) 2006-08-25

Family

ID=33492257

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06105580.9A HK1085511A1 (en) 2003-06-02 2006-05-15 Complement inhibitors from ticks

Country Status (13)

Country Link
US (5) US7884188B2 (es)
EP (1) EP1629098B1 (es)
JP (1) JP4772667B2 (es)
AT (1) ATE427356T1 (es)
AU (1) AU2004242759B2 (es)
BR (1) BRPI0410876B8 (es)
CA (1) CA2526083C (es)
DE (1) DE602004020334D1 (es)
ES (1) ES2324993T3 (es)
HK (1) HK1085511A1 (es)
MX (1) MXPA05012880A (es)
NZ (1) NZ544163A (es)
WO (1) WO2004106369A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544163A (en) * 2003-06-02 2009-06-26 Evolutec Ltd Complement inhibitors
JP5137053B2 (ja) 2004-02-10 2013-02-06 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬
US8088579B2 (en) 2005-02-14 2012-01-03 University Of Iowa Research Foundation Complement factor H for diagnosis of age-related macular degeneration
AU2006249835B2 (en) 2005-05-26 2011-09-08 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
KR101152557B1 (ko) 2005-12-12 2012-09-07 에이씨 이뮨 에스.에이. 치료 백신
PL2061501T3 (pl) * 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
ES2545775T3 (es) * 2007-02-05 2015-09-15 Apellis Pharmaceuticals, Inc. Análogos de compstatina para uso en el tratamiento de afecciones inflamatorias del sistema respiratorio
AU2008251943B2 (en) 2007-03-14 2013-09-05 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US20090324585A1 (en) * 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
CN101928709B (zh) * 2009-06-24 2012-05-23 中国农业科学院上海兽医研究所 一种亚洲璃眼蜱的组胺结合蛋白HaHBP的基因序列和重组表达与应用
RS20120461A1 (en) 2009-07-02 2013-06-28 Musc Foundation For Research Development METHODS FOR STIMULATION OF LIVER REGENERATION
PL2521562T3 (pl) * 2010-01-08 2020-04-30 Volution Immuno Pharmaceuticals Sa Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
WO2011112993A2 (en) 2010-03-11 2011-09-15 University Of Louisville Research Foundation, Inc. Methods of predicting and decreasing the risk of pregnancy loss
WO2012078968A2 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
EP2720708A4 (en) 2011-06-20 2015-10-14 Univ Saint Louis AIMING AT THE NEUROMUSCULAR END PLATE FOR TREATMENT PURPOSES
AU2012272706B2 (en) 2011-06-22 2017-07-06 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
LT2817329T (lt) 2012-02-20 2019-04-10 Swedish Orphan Biovitrum Ab (Publ) Polipeptidai, prisijungiantys prie žmogaus komplemento c5
EP2855529A4 (en) 2012-05-24 2015-12-09 Alexion Pharma Inc HUMANIZED ANTI-FACTOR B ANTIBODIES
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
US20200325449A1 (en) 2016-06-02 2020-10-15 The Cleveland Clinic Foundation Complement inhibition for improving cell viability
WO2017218515A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
US11730792B2 (en) 2017-04-21 2023-08-22 Volution Immuno Pharmaceuticals Sa Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA)
CA3083113A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
WO2020053206A1 (en) 2018-09-10 2020-03-19 Volution Immuno Pharmaceuticals Sa Coversin for use in the treatment of rheumatic diseases
GB201905810D0 (en) 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
EP4034237A1 (en) 2019-09-27 2022-08-03 Volution Immuno Pharmaceuticals SA Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (hsct-tma)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017099A1 (en) 1992-02-27 1993-09-02 Merck & Co., Inc. Protein for inhibiting collagen-stimulated platelet aggregation
US7884066B2 (en) * 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
NZ544163A (en) * 2003-06-02 2009-06-26 Evolutec Ltd Complement inhibitors

Also Published As

Publication number Publication date
CA2526083A1 (en) 2004-12-09
MXPA05012880A (es) 2006-02-22
US9834585B2 (en) 2017-12-05
JP2007536894A (ja) 2007-12-20
DE602004020334D1 (de) 2009-05-14
JP4772667B2 (ja) 2011-09-14
ES2324993T3 (es) 2009-08-21
US20070141573A1 (en) 2007-06-21
BRPI0410876B8 (pt) 2023-01-24
NZ544163A (en) 2009-06-26
ATE427356T1 (de) 2009-04-15
US7884188B2 (en) 2011-02-08
EP1629098B1 (en) 2009-04-01
BRPI0410876B1 (pt) 2020-11-03
AU2004242759A1 (en) 2004-12-09
CA2526083C (en) 2017-01-17
EP1629098A2 (en) 2006-03-01
AU2004242759B2 (en) 2009-11-26
US8993264B2 (en) 2015-03-31
US20160096870A1 (en) 2016-04-07
US20220363726A1 (en) 2022-11-17
BRPI0410876A (pt) 2006-07-04
US20180127472A1 (en) 2018-05-10
WO2004106369A3 (en) 2005-02-17
WO2004106369A2 (en) 2004-12-09
US20110263482A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
HK1085511A1 (en) Complement inhibitors from ticks
TNSN05044A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
WO2003105840A3 (en) SPHINGOSINE KINASE INHIBITORS
GB0223040D0 (en) Therapeutic compounds
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
NO20034056D0 (no) Proliferative sykdommer
MXPA05012812A (es) Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp).
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
DK1420801T3 (da) Anvendelse af fucaner til behandling af adhæsioner, arthritis og psoreasis
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
IS2923B (is) Aðferðir til að meðhöndla eða fyrirbyggja með 2,4-pýrimidíndíamínefnasamböndum sjálfsónæmissjúkdóma
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
EP1553951A4 (en) COMPOSITIONS CONTAINING A JNK INHIBITOR FOR TREATING, PREVENTING, MANAGING AND / OR MODIFYING PAIN, AND METHODS OF USE THEREOF
DK1581235T3 (da) Anvendelse af spongosin (2-methoxyadenosin) til behandling af smerte i særdeleshed hyperalgesi
ATE443044T1 (de) Tace inhibitoren
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
WO2004060878A3 (en) Inhibitors of phosphatases
HUP0401633A2 (hu) Irbesartan alkalmazása pulmonális magas vérnyomás megelőzésére vagy kezelésére alkalmas gyógyszerkészítmény előállítására